January 2005 in “Pediatric Dermatology” Alopecia areata in infants may be more common than previously thought.
Topical corticosteroid treatment showed no significant difference from placebo in treating alopecia areata in children.
Alopecia areata often starts around age 23, can be permanent in 30% of cases, and treatments are usually temporary.
10 citations
,
March 2014 in “Scandinavian journal of clinical and laboratory investigation” Malondialdehyde-modified DNA may trigger an immune response in alopecia areata patients.
27 citations
,
April 2005 in “Journal of Chemotherapy” Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
September 2017 in “Journal of Dermatology & Cosmetology” Hepatitis C treatment may cause frontal fibrosing alopecia.
April 2026 in “Boletín Médico Del Hospital Infantil de México (English Edition)”
March 2026 in “American Journal of Clinical Dermatology”
September 2022 in “Dermatology and therapy” Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.
11 citations
,
December 2013 in “International Journal of Dermatology” IL16 gene variations may affect the risk of alopecia areata in Koreans.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
January 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” High levels of HSP70 and IL-15 are linked to more severe alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
July 2023 in “Australasian Journal of Dermatology” The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.
November 2025 in “Journal of Investigative Dermatology” Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
89 citations
,
August 2018 in “JAMA Dermatology” Contact immunotherapy can improve hair regrowth in alopecia areata patients.
22 citations
,
September 2024 in “Chemical Engineering Journal” A new microneedle patch effectively and safely treats alopecia areata.
4 citations
,
August 2024 in “Skin Research and Technology” The study was retracted.
3 citations
,
May 2023 in “Journal of the American Academy of Dermatology” Certain drugs can cause hair loss, but stopping the drug usually leads to hair regrowth.
1 citations
,
June 2025 in “Journal of Patient Experience” Alopecia areata greatly affects quality of life, with many experiencing mental health issues and lacking professional support.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
February 2026 in “Stem Cell Research & Therapy” Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.
November 2025 in “Journal of Investigative Dermatology” November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
August 2025 in “Australasian Journal of Dermatology” Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.